Patents Examined by S. Devi
  • Microbial reductive dehalogenation of vinyl chloride
    Patent number: 8647824
    Abstract: Compositions and methods are provided that relate to the bioremediation of chlorinated ethenes, particularly the bioremediation of vinyl chloride by Dehalococcoides-like organisms. An isolated strain of bacteria, Dehalococcoides sp. strain VS, that metabolizes vinyl chloride is provided; the genetic sequence of the enzyme responsible for vinyl chloride dehalogenation; methods of assessing the capability of endogenous organisms at an environmental site to metabolize vinyl chloride; and a method of using the strains of the invention for bioremediation.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: February 11, 2014
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Alfred M. Spormann, Jochen A. Müller, Bettina M. Rosner, Gregory Von Abendroth, Galit Meshulam-Simon, Perry L. McCarty
  • Multiple antigenic peptides immunogenic against
    Patent number: 8642048
    Abstract: The invention provides a nucleic acid encoding the 37-kDa pneumococcal surface adhesion A protein (PsaA) from Streptococcus pneumoniae. The invention also provides purified polypeptides encoded by the nucleic acid encoding the 37-kDa protein from and the nucleic acids comprising unique fragment of at least 10 nucleotides of the 37-kDa protein. Additionally, multiple antigenic peptides that provide protection against S. pneumoniae challenge are provided. These multiple antigen peptides comprise the peptides that immunospecifically bind to the monoclonal antibodies. Also provided are vaccines comprising such immunogenic peptides, and methods of conferring protective immunity against Streptococcus pneumoniae infection by administering therapeutic composition comprising the immunogenic peptides of the invention.
    Type: Grant
    Filed: January 27, 2009
    Date of Patent: February 4, 2014
    Assignee: The United States of America, as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Edwin W. Ades, Scott E. Johnson, Danny L. Jue, Jacquelyn S. Sampson, George M. Carlone
  • Pathogen hemoglobin receptor specificity for human hemoglobin
    Patent number: 8632988
    Abstract: A method of measuring binding between hemoglobin and a microbe of interest includes: providing hemoglobin from a source of interest; contacting the hemoglobin with a microbe of interest; and measuring the binding affinity between the hemoglobin and the microbe, wherein the binding affinity is indicative of microbe virulence in the presence of the hemoglobin.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: January 21, 2014
    Assignee: Vanderbilt University
    Inventors: Eric P. Skaar, Glib Pishchany
  • Nucleic acids and proteins from
    Patent number: 8632784
    Abstract: Novel proteins from Streptococcus pneumoniae are described, together with nucleic acid sequences encoding them. Their use in vaccines and in screening methods is also described.
    Type: Grant
    Filed: June 7, 2006
    Date of Patent: January 21, 2014
    Assignee: Sanofi Pasteur Limited
    Inventors: Richard William Falla Le Page, Jeremy Mark Wells, Sean Bosco Hanniffy, Philip Michael Hansbro
  • adhesion molecule
    Patent number: 8629249
    Abstract: A polypeptide, designated as “Streptococcus uberis Adhesion Molecule” (SUAM), and fragments of SUAM, prevent internalization and adherence of Streptococcus uberis and other streptococcal pathogens to cells. The SUAM polypeptide and fragments may be used diagnostically and therapeutically. Nucleic acid sequences encoding the SUAM polypeptide and fragments are included in the invention.
    Type: Grant
    Filed: June 7, 2010
    Date of Patent: January 14, 2014
    Assignee: University of Tennessee Research Foundation
    Inventors: Stephen P. Oliver, Raul A. Almeida, Douglas A. Luther, Hee-Myung Park
  • Vaccine for protection against bacteria of various serotypes
    Patent number: 8628766
    Abstract: The present invention pertains to the use of Streptococcus suis antigens corresponding to Streptococcus suis bacteria of a predetermined serotype in the manufacture of a vaccine for administration to a sow or gilt, to protect a piglet through the intake of colostrum of the said sow or gilt, against a disorder arising from Streptococcus suis bacteria of a serotype other than the predetermined one. The invention also pertains to Streptococcus suis antigens for use in the manufacture of such a vaccine.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: January 14, 2014
    Assignee: Intervet International B.V.
    Inventors: Henricus Leo Bernardus Maria Klaasen, Ruud Philip Antoon Maria Segers
  • Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
    Patent number: 8623380
    Abstract: The invention provides a diphtheria, tetanus and pertussis vaccine comprising a low dose of each of diphtheria toxoid (D), tetanus toxoid (T), pertussis toxin (PT), filamentous haemagglutinin (FHA) and pertactin (69K). The vaccine maintains an ability to prevent pertussis while showing exceptionally low reactogenicity. Combination vaccines comprising additional antigens are also provided.
    Type: Grant
    Filed: May 4, 2004
    Date of Patent: January 7, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Patrick Florent, Jean Stephenne, Christian Vandecasserie
  • Recombinant antigens for diagnosis and prevention of spotted fever rickettsiae
    Patent number: 8623383
    Abstract: The invention relates to the construction of recombinant, immunodominant polypeptides against spotted fever group Rickettsia. The invention also relates to a method for the use of the recombinant proteins, either singly or in combination, in detection and diagnostic assays of spotted fever. The proteins can also be used to induce immune response against spotted fever group Rickettsia.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: January 7, 2014
    Assignee: The United States of America as represented by the Secretary of the Navy
    Inventor: Wei-Mei Ching
  • preparations and the treatment of autoimmune conditions
    Patent number: 8617536
    Abstract: This document provides methods and materials related to Prevotella histicola preparations. For example, Prevotella histicola preparations in the form of an oral medicament or dietary supplement (e.g., a pill, tablet, capsule) are provided. In addition, methods and materials for using a Prevotella histicola preparation provided herein as an anti-inflammatory agent are provided.
    Type: Grant
    Filed: October 27, 2010
    Date of Patent: December 31, 2013
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Joseph A. Murray, Eric V. Marietta, Susan H. Barton, Veena Taneja, Ashutosh Mangalam
  • Gamma-glutamyl transpeptidase attenuated
    Patent number: 8609108
    Abstract: The present invention relates to a mutated Francisella bacterium, wherein the ggt gene is silenced or deleted; pharmaceutical compositions comprising the same, in particular, vaccine compositions, and use of the bacterium and compositions for treatment and/or prophylaxis, and in particular, the treatment or prophylaxis of tularemia.
    Type: Grant
    Filed: April 14, 2010
    Date of Patent: December 17, 2013
    Assignee: The Secretary of State for Defence
    Inventors: Helen Le Butt, Phillip Matthew Ireland, Petra Claire Farquar Oyston
  • Diagnosis of infection based on detection of bacterial secreted biomarkers
    Patent number: 8591899
    Abstract: A novel and rapid diagnostic method for anthrax infection is provided. Three B. anthracis gene products are described, as well as antibodies against the same, which may be used for the detection and monitoring of anthrax infection. Kits for the diagnosis of anthrax are also provided.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: November 26, 2013
    Assignee: State of Israel, Represented by Prime Minister's Office, Israel Institute for Biological Research
    Inventors: Avigdor Shafferman, Ofer Cohen, Theodor Chitlaru, Sagit Sela-Abramovich, Orit Gat
  • Methods and compositions for mycoplasma pneumoniae exotoxins
    Patent number: 8586046
    Abstract: The present invention provides a Mycoplasma pneumoniae community acquired respiratory distress syndrome (CARDS) toxin, biologically active fragments/domains of the CARDS toxin, antibodies to the CARDS toxin and nucleic acids encoding the CARDS toxin. Also provided are methods of diagnosing, treating and/or preventing infection by Mycoplasma pneumoniae using the compositions provided herein.
    Type: Grant
    Filed: December 29, 2011
    Date of Patent: November 19, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joel Barry Baseman, Thirumalai Regasamy Kannan
  • Immunogenic compositions for the prevention and treatment of meningococcal disease
    Patent number: 8574597
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: November 5, 2013
    Assignee: Wyeth LLC
    Inventor: Gary Warren Zlotnick
  • Immunogenic compositions for the prevention and treatment of meningococcal disease
    Patent number: 8563006
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: October 22, 2013
    Assignee: Wyeth Holdings Corporation
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Immunogenic compositions for the prevention and treatment of meningococcal disease
    Patent number: 8563007
    Abstract: The present invention relates to Neisseria ORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection by Neisseria meningitidis serogroup B.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: October 22, 2013
    Assignee: Wyeth Holdings Corporation
    Inventors: Gary W. Zlotnick, Leah Diane Fletcher, John Erwin Farley, Liesel A. Bernfield, Robert J. Zagursky, Benjamin J. Metcalf
  • Recombinant alpha-hemolysin polypeptide of , having a deletion in the stem domain and heterologous sequences inserted
    Patent number: 8545853
    Abstract: It refers to a recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, comprising a deletion in the stem domain, wherein at least one heterologous sequence is inserted in a region selected from the group consisting of regions defined by amino acid position of 108 to 151, 1 to 5, 288 to 293, 43 to 48, 235 to 240, 92 to 97, 31 to 36,or 156 to 161 of SEQ ID NO: 1, with the proviso that, if the heterologous sequence contains five or more consecutive histidines the moiety of the heterologous sequence other than the moiety of five or more consecutive histidines has a minimum length of 11 amino acids; or a variant thereof comprising 1-50 amino acids added, substituted or deleted in SEQ ID NO. 1 and the activity to form oligomers and to bind to lipidic bilayers. It also provides a medicament and vaccine comprising said recombinant polypeptide.
    Type: Grant
    Filed: January 15, 2010
    Date of Patent: October 1, 2013
    Assignees: Universite de Liege, Centre d'Economie Rurale, Universite Libre de Bruxelles
    Inventors: Patrice Filee, Noureddine Rhazi, Moreno Galleni, Bernard Taminiau, Olivier Jolois, Alfred Collard, Alain Jacquet
  • Pharmaceutical compositions and methods to vaccinate against candidiasis
    Patent number: 8541008
    Abstract: A Candida albicans bloodstream infections cause significant morbidity and mortality in hospitalized patients. Filament formation and adherence to host cells are critical virulence factors of C. albicans. Multiple filamentation regulatory pathways have been discovered, however the downstream effectors of these regulatory pathways remain unknown. The cell surface proteins in the ALS group are downstream effectors of the filamentation regulatory pathway. Particularly, Als1p mediates adherence to endothelial cells in vitro and is required for virulence. The blocking of adherence by the organism is described resulting from the use of a composition and method disclosed herein. Specifically, a pharmaceutical composition comprised of a gene, gene product, or specific antibody to the ALS gene family is administered as a vaccine to generate an immune response capable of blocking adherence of the organism.
    Type: Grant
    Filed: September 13, 2002
    Date of Patent: September 24, 2013
    Assignee: Los Angeles BioMedical Research Institute at Harbor-UCLA Medical Center
    Inventors: John E. Edwards, Jr., Scott G. Filler, Donald C. Sheppard, Ashraf S. Ibrahim, Yue Fu, Bradley J. Spellberg
  • Vaccine
    Patent number: 8535688
    Abstract: The invention relates to a vaccine for the treatment of disease caused by Neisseria, the vaccine including one or more immunogenic components for Neisseria serogroups, as well as antibodies to the immunogenic components and methods of preventing and treating Neisseria infections. The immunogens are based on elements of the inner core lipopolysaccharide.
    Type: Grant
    Filed: December 7, 2011
    Date of Patent: September 17, 2013
    Assignee: Isis Innovation Limited
    Inventors: Joyce Susan Plested, Michael Paul Jennings, Margaret Ann Jaqueline Gidney, Andrew David Cox, James Clare Richards, Richard Edward Moxon
  • antigens and compositions
    Patent number: 8524251
    Abstract: The invention provides proteins from Neisseria meningitidis, including the amino acid sequences and the corresponding nucleotide sequences. The proteins are predicted to be useful antigens for vaccines and/or diagnostics.
    Type: Grant
    Filed: January 26, 2012
    Date of Patent: September 3, 2013
    Assignees: J. Craig Venter Institute, Inc., Novartis AG
    Inventors: Claire Fraser, Cesira Galeotti, Guido Grandi, Erin Hickey, Vega Masignani, Marirosa Mora, Jeremy Petersen, Mariagrazia Pizza, Rino Rappuoli, Giulio Ratti, Vincenzo Scarlato, Maria Scarselli, Herve Tettelin, J. Craig Venter
  • Treatment of immune disease by mucosal delivery of antigents using genetically modified
    Patent number: 8524246
    Abstract: The present invention relates to the treatment of autoimmune and allergic diseases by mucosal delivery by micro-organism, in particular Lactococcus lactis, of secreted immunodominant antigens.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: September 3, 2013
    Assignee: Actogenix N.V.
    Inventors: Pieter Rottiers, Veerle Snoeck